-
Something wrong with this record ?
Novel germline JAK2R715T mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon
J. Song, L. Lanikova, SJ. Kim, N. Papadopoulos, J. Meznarich, SN. Constantinescu, B. Parsegov, JF. Prchal, JT. Prchal
Language English Country United States
Document type Journal Article, Case Reports
Grant support
24-11730S
Grantová Agentura České Republiky
LX22NPO5102
Next Generation EU
16/21-073
Ludwig Institute for Cancer Research
n°T.0043.21
Projet de recherche FNRS
MPN Research Foundation
Fonds De La Recherche Scientifique - FNRS
F 44/8/5 - MCF/UIG - 10955
Walloon excellence in life sciences and biotechnology
NU21/03/00338
Czech Health Research Council
NLK
Free Medical Journals
from 1998 to 1 year ago
Wiley Free Content
from 1996 to 1 year ago
PubMed
38629639
DOI
10.1002/ajh.27311
Knihovny.cz E-resources
- MeSH
- Gain of Function Mutation MeSH
- Adult MeSH
- Interferon-alpha therapeutic use MeSH
- Janus Kinase 2 * genetics MeSH
- Humans MeSH
- Polycythemia * genetics drug therapy MeSH
- Polycythemia Vera genetics drug therapy MeSH
- Pedigree MeSH
- Germ-Line Mutation * MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
Polycythemia vera (PV) is a clonal disorder arising from the acquired somatic mutations of the JAK2 gene, including JAK2V617F or several others in exon 12. A 38-year-old female had a stroke at age 32 and found to have elevated hemoglobin, normal leukocytes, normal platelets, and tested negative for JAK2V617F and exon 12 mutations. Next generation sequencing revealed a novel mutation: JAK2R715T in the pseudokinase domain (JH2) at 47.5%. Its presence in her nail DNA confirmed a germline origin. Her mother and her son similarly had erythrocytosis and a JAK2R715T mutation. Computer modeling indicated gain-of-function JAK2 activity. The propositus and her mother had polyclonal myelopoiesis, ruling out another somatic mutation-derived clonal hematopoiesis. Some erythroid progenitors of all three generations grew without erythropoietin, a hallmark of PV. The in vitro reporter assay confirmed increased activity of the JAK2R715T kinase. Similar to PV, the JAK2R715T native cells have increased STAT5 phosphorylation, augmented transcripts of prothrombotic and inflammatory genes, and decreased KLF2 transcripts. The propositus was not controlled by hydroxyurea, and JAK2 inhibitors were not tolerated; however, Ropeginterferon-alfa-2b (Ropeg-IFN-α) induced a remission. Ropeg-IFN-α treatment also reduced JAK2 activity in the propositus, her mother and JAK2V617F PV subjects. We report dominantly inherited erythrocytosis secondary to a novel germline JAK2R715T gain-of-function mutation with many but not all comparable molecular features to JAK2V617F PV. We also document a previously unreported inhibitory mechanism of JAK2 signaling by Ropeg-IFN-α.
e Duve Institute Brussels Belgium
Ludwig Institute for Cancer Research Brussels Belgium
McGill University Montreal Quebec City Quebec Canada
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013395
- 003
- CZ-PrNML
- 005
- 20240905133307.0
- 007
- ta
- 008
- 240725s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ajh.27311 $2 doi
- 035 __
- $a (PubMed)38629639
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Song, Jihyun $u Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA $1 https://orcid.org/0000000212690892
- 245 10
- $a Novel germline JAK2R715T mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon / $c J. Song, L. Lanikova, SJ. Kim, N. Papadopoulos, J. Meznarich, SN. Constantinescu, B. Parsegov, JF. Prchal, JT. Prchal
- 520 9_
- $a Polycythemia vera (PV) is a clonal disorder arising from the acquired somatic mutations of the JAK2 gene, including JAK2V617F or several others in exon 12. A 38-year-old female had a stroke at age 32 and found to have elevated hemoglobin, normal leukocytes, normal platelets, and tested negative for JAK2V617F and exon 12 mutations. Next generation sequencing revealed a novel mutation: JAK2R715T in the pseudokinase domain (JH2) at 47.5%. Its presence in her nail DNA confirmed a germline origin. Her mother and her son similarly had erythrocytosis and a JAK2R715T mutation. Computer modeling indicated gain-of-function JAK2 activity. The propositus and her mother had polyclonal myelopoiesis, ruling out another somatic mutation-derived clonal hematopoiesis. Some erythroid progenitors of all three generations grew without erythropoietin, a hallmark of PV. The in vitro reporter assay confirmed increased activity of the JAK2R715T kinase. Similar to PV, the JAK2R715T native cells have increased STAT5 phosphorylation, augmented transcripts of prothrombotic and inflammatory genes, and decreased KLF2 transcripts. The propositus was not controlled by hydroxyurea, and JAK2 inhibitors were not tolerated; however, Ropeginterferon-alfa-2b (Ropeg-IFN-α) induced a remission. Ropeg-IFN-α treatment also reduced JAK2 activity in the propositus, her mother and JAK2V617F PV subjects. We report dominantly inherited erythrocytosis secondary to a novel germline JAK2R715T gain-of-function mutation with many but not all comparable molecular features to JAK2V617F PV. We also document a previously unreported inhibitory mechanism of JAK2 signaling by Ropeg-IFN-α.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a aktivační mutace $7 D000073659
- 650 12
- $a zárodečné mutace $7 D018095
- 650 _2
- $a interferon alfa $x terapeutické užití $7 D016898
- 650 12
- $a Janus kinasa 2 $x genetika $7 D053614
- 650 _2
- $a rodokmen $7 D010375
- 650 12
- $a polycytemie $x genetika $x farmakoterapie $7 D011086
- 650 _2
- $a polycythaemia vera $x genetika $x farmakoterapie $7 D011087
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a kazuistiky $7 D002363
- 700 1_
- $a Lanikova, Lucie $u Department of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000228458692
- 700 1_
- $a Kim, Soo Jin $u Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA $1 https://orcid.org/0000000241741679
- 700 1_
- $a Papadopoulos, Nicolas $u Ludwig Institute for Cancer Research, Brussels, Belgium $u de Duve Institute, Brussels, Belgium $1 https://orcid.org/000000017869862X
- 700 1_
- $a Meznarich, Jessica $u Division of Hematology-Oncology, Department of Pediatrics, University of Utah and Primary Children's Hospital, Salt Lake City, Utah, USA $1 https://orcid.org/0000000172224351
- 700 1_
- $a Constantinescu, Stefan N $u Ludwig Institute for Cancer Research, Brussels, Belgium $u de Duve Institute, Brussels, Belgium $u Nuffield Department of Medicine, Oxford University, Oxford, UK $u WELBIO Department, WEL Research Institute, Wavre, Belgium $1 https://orcid.org/0000000285992699
- 700 1_
- $a Parsegov, Brynn $u Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA $1 https://orcid.org/0009000522260561
- 700 1_
- $a Prchal, Jaroslav F $u McGill University Montreal, Quebec City, Quebec, Canada
- 700 1_
- $a Prchal, Josef T $u Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA $1 https://orcid.org/0000000280192940
- 773 0_
- $w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 99, č. 7 (2024), s. 1220-1229
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38629639 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133301 $b ABA008
- 999 __
- $a ok $b bmc $g 2143294 $s 1225261
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 99 $c 7 $d 1220-1229 $e 20240417 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
- GRA __
- $a 24-11730S $p Grantová Agentura České Republiky
- GRA __
- $a LX22NPO5102 $p Next Generation EU
- GRA __
- $a 16/21-073 $p Ludwig Institute for Cancer Research
- GRA __
- $a n°T.0043.21 $p Projet de recherche FNRS
- GRA __
- $p MPN Research Foundation
- GRA __
- $p Fonds De La Recherche Scientifique - FNRS
- GRA __
- $a F 44/8/5 - MCF/UIG - 10955 $p Walloon excellence in life sciences and biotechnology
- GRA __
- $a NU21/03/00338 $p Czech Health Research Council
- LZP __
- $a Pubmed-20240725